Status:
COMPLETED
Pilot Study of Edaravone to Treat Acute Myocardial Infarction
Lead Sponsor:
Kumamoto University
Collaborating Sponsors:
Japan Heart Foundation
Conditions:
Myocardial Infarction
Reperfusion Injury
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now i...
Detailed Description
Initial AMI patients were randomly assigned to receive 30 mg of edaravone or a placebo intravenously just before reperfusion. We compared infarct size, using serial determination of serum biomarkers a...
Eligibility Criteria
Inclusion
- Initial AMI patients admitted to the investigators' institution within 6 hours of symptom onset and treated primary percutaneous coronary intervention.
Exclusion
- Renal insufficiency defined as serum creatinine \> 1.2 mg/dl and altered hepatic function defined as serum asparate aminotransferase \> 50 IU/L, alanine aminotransferase \> 50 IU/L and total bilirubin \> 1.2 mg/dl.
Key Trial Info
Start Date :
April 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
104 Patients enrolled
Trial Details
Trial ID
NCT00265239
Start Date
April 1 2001
End Date
June 1 2007
Last Update
September 15 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University
Kumamoto, Japan, 860-8556